Lesser Poland Cracovian Heart Failure Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorJagiellonian University

About this trial

The goal of Lesser Poland Cracovian Heart Failure Registry (LECRA-HF) is to expand the knowledge about acute heart failure (AHF) and its long-term prognosis.

The main questions are:

* assessment of long-term prognosis of AHF and its determinants * determination of the optimal AHF treatment methods * assessment of indications for invasive coronary arteries diagnostics and revascularization and their long-term effects * analysis of the particular HF subtypes (HFimpEF, HFpEF, HFsnEF, HFrEF, HFmrEF)

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

hospitalization due to acute heart failure

> 18 years of age

Disqualifiers

inability to give informed consent to participate in the registry

Trial population

The study population consists of hospitalized patients with acute heart failure who are over 18 years of age, both women and men. Patients will be initially categorized into one of three groups based on the current European Society of Cardiology (ESC) heart failure guidelines based on left ventricular ejection fraction (LVEF) values: patients with reduced (LVEF ≤40%), mildly reduced (LVEF 41-49%) and preserved (LVEF ≥50%) ejection fraction.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

2,500 Participants
are grouped into 1 trial group
Group A: LECRA-HF patients

Trial outcomes

Primary outcomes

1

All-cause mortality

Mortality due to all causes

Time frame
2 years

Secondary outcomes

1

Cardiovascular mortality

Mortality due to CV causes

Time frame
2 years
2

HF rehospitalizations

Rehospitalizations related to HF decompensation

Time frame
2 years

Other outcomes

1

LVEF increase >10% in the follow-up echocardiography

In accordance with HFimpEF definition

Time frame
2 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.